The $75M raise extends cash runway but at severe dilution; monitor the underwriters' option exercise and the company's path to first commercial revenue from VOCERYQ. The 90-day lock-up may limit near-term selling pressure from insiders.
Drug in focus
INO drug pipeline →VOCERYQ
● Neutral Named in this press release- Impact
- Phase
- Approved (Accelerated Approval)
- Time to market
- Already approved (October 30, 2026). Commercial launch expected in Q1 2027, with initial ordering and shipping in approximately 60 days.
- Next catalyst
- None dated
What to watchWith the approval binary resolved, the next key events are the confirmatory study protocol submission (due end of 2026, final by mid-2027) and the commercial launch in Q1 2027. Monitor initial prescription uptake and payer coverage in the first two quarters post-launch, as Inovio's cash runway extends only into late Q1 2027, leaving little margin for a slow commercial start.
How the stock moved after the report
⚠ Clustered BEARISH VIEWSTOCK ABOVE ENTRY AT T+5- T+0 · Nov 6 $1.22entry
- T+1 · 8d ago +24.28%α +21.91% · $1.51
- T+5 · 4d ago +17.70%α +15.10% · $1.43
- T+6 · todayOpen
- T+20 · in 20d Pending
- T+60 · in 3mo Pending
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Inovio priced a $75M underwritten public offering of 58.7M shares at $1.05/share plus pre-funded warrants, following the October 30 FDA accelerated approval of VOCERYQ (INO-3107) for RRP. The offering from the $300M shelf, underwritten by Jefferies and Piper Sandler, represents ~34% dilution based on shares outstanding before the offering, underscoring ongoing capital needs for a pre-revenue biotech with a going concern warning.
Key Financial Metrics
Key Facts
- Priced 58,747,235 shares at $1.05/share and 12,681,337 pre-funded warrants at $1.049 each
- Gross proceeds expected ~$75M before underwriting discounts and commissions
- Underwriters have 30-day option to purchase up to 10,714,285 additional shares
- Offering expected to close on or about November 9, 2026
- Jefferies and Piper Sandler are joint book-running managers; H.C. Wainwright is lead manager
- Offering follows October 30, 2026 FDA accelerated approval of VOCERYQ (INO-3107) for RRP
- Preliminary Q3 2026 cash balance was $48.4M with a going concern warning
- 90-day lock-up for company and insiders per the 424B5 filing
Financial Impact
$75M gross proceeds from offering; dilution of ~34% based on shares outstanding before the offering (58.7M new shares vs ~172M pre-offering, plus warrants)
Risk Factors
- Dilution of ~34% from the offering, with additional overhang from the underwriters' option
- Going concern warning remains despite the capital raise; pre-revenue status with only one approved product
- Market conditions could worsen, making future capital raises more difficult or expensive
- The offering was priced at $1.05, below the prior day's close (not stated, but typical discount for at-the-market offerings)
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-prn-302931699 |
Track record
20 reports on INO
8 of 13 bullish or bearish reports moved the stock their way by T+5. Best: +46.23% at T+20 after the Jul 2, 2026 report. 9 of 14 went positive at some point.
Filters
- Nov 16, 2026today SC 13G Neutral 4/10 Entry $1.39 Now $1.40 +0.72% settles Nov 24
- Nov 16, 2026today SC 13G/A Bearish 4/10 Entry $1.40 Now $1.40 −0.01% settles Nov 24
- Nov 16, 2026today SC 13G/A Neutral 3/10 Entry $1.41 Now $1.40 −0.71% settles Nov 23
- Nov 10, 20266d ago 8-K Bearish 5/10 Entry $1.48 Now $1.40 +5.08% settles Nov 18
- Nov 9, 20267d ago 8-K Bearish 5/10 Entry $1.51 to $1.40 Now $1.40 +7.28% ▲ +7.28% +5.59% vs SPY
- Nov 6, 202610d ago 424B5 Bearish 5/10 Entry $1.51 to $1.40 Now $1.40 +7.28% ▲ +7.28% +5.59% vs SPY
- Nov 5, 202611d ago Press Release Bearish 6/10 Viewing Entry $1.22 to $1.43 Now $1.40 −15.23% ▼ −17.70% −15.10% vs SPY
- Nov 5, 202611d ago 8-K Bearish 5/10 Entry $1.22 to $1.43 Now $1.40 −15.23% ▼ −17.70% −15.10% vs SPY
- Nov 5, 202611d ago 424B5 Bearish 4/10 Entry $1.22 to $1.43 Now $1.40 −15.23% ▼ −17.70% −15.10% vs SPY
- Nov 5, 202611d ago Press Release Bearish 4/10 Entry $1.22 to $1.43 Now $1.40 −15.23% ▼ −17.70% −15.10% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers